Tazeen Ahmad
Stock Analyst at B of A Securities
(2.43)
# 2,201
Out of 4,810 analysts
198
Total ratings
41.61%
Success rate
-2.4%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $63 → $68 | $62.09 | +9.52% | 8 | Apr 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $302 → $325 | $230.93 | +40.74% | 3 | Mar 21, 2025 | |
| STRO Sutro Biopharma | Downgrades: Underperform | $11 → $1 | $0.58 | +72.56% | 2 | Mar 14, 2025 | |
| ARVN Arvinas | Maintains: Buy | $54 → $28 | $7.58 | +269.39% | 2 | Mar 12, 2025 | |
| PTCT PTC Therapeutics | Upgrades: Neutral | $41 → $55 | $46.94 | +17.17% | 16 | Mar 11, 2025 | |
| MRUS Merus | Maintains: Buy | $73 → $70 | $43.22 | +61.96% | 5 | Mar 10, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $42 → $40 | $3.10 | +1,190.32% | 4 | Mar 10, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $30 → $28 | $13.17 | +112.60% | 2 | Mar 10, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $184 → $179 | $96.16 | +86.15% | 3 | Feb 7, 2025 | |
| PRTA Prothena Corporation | Maintains: Neutral | $26 → $22 | $9.59 | +129.41% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $11.95 | +84.10% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.31 | +129.01% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $61 → $47 | $18.97 | +147.76% | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $58.46 | +53.95% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.90 | +117.39% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $6 | $7.54 | -20.42% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $191 | $153.92 | +24.09% | 8 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $99.00 | +51.52% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $3.04 | -34.21% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $605.38 | +0.27% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $213 | $54.42 | +291.40% | 21 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $35.34 | +115.05% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $14.99 | +46.76% | 13 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $1.00 | +1,303.93% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $1.54 | +549.35% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.12 | +435.71% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.53 | +99.20% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $13.94 | -21.09% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $7.40 | +35.14% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $1.21 | +65.29% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.75 | +697.55% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $9.75 | +53.85% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $29.67 | +102.22% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.92 | +1,648.63% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $6.05 | +610.74% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $147.06 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $7.35 | +3,981.63% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $0.74 | +1,109.03% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $24.88 | +92.93% | 6 | Oct 10, 2018 |
Rhythm Pharmaceuticals
Apr 10, 2025
Maintains: Buy
Price Target: $63 → $68
Current: $62.09
Upside: +9.52%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $302 → $325
Current: $230.93
Upside: +40.74%
Sutro Biopharma
Mar 14, 2025
Downgrades: Underperform
Price Target: $11 → $1
Current: $0.58
Upside: +72.56%
Arvinas
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $7.58
Upside: +269.39%
PTC Therapeutics
Mar 11, 2025
Upgrades: Neutral
Price Target: $41 → $55
Current: $46.94
Upside: +17.17%
Merus
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $43.22
Upside: +61.96%
4D Molecular Therapeutics
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $3.10
Upside: +1,190.32%
Denali Therapeutics
Mar 10, 2025
Maintains: Buy
Price Target: $30 → $28
Current: $13.17
Upside: +112.60%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $96.16
Upside: +86.15%
Prothena Corporation
Dec 19, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $9.59
Upside: +129.41%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $11.95
Upside: +84.10%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.31
Upside: +129.01%
Nov 6, 2024
Maintains: Buy
Price Target: $61 → $47
Current: $18.97
Upside: +147.76%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $58.46
Upside: +53.95%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.90
Upside: +117.39%
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $7.54
Upside: -20.42%
Sep 23, 2024
Maintains: Buy
Price Target: $175 → $191
Current: $153.92
Upside: +24.09%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $99.00
Upside: +51.52%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $3.04
Upside: -34.21%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $605.38
Upside: +0.27%
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $54.42
Upside: +291.40%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $35.34
Upside: +115.05%
May 10, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $14.99
Upside: +46.76%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $1.00
Upside: +1,303.93%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $1.54
Upside: +549.35%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.12
Upside: +435.71%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $7.53
Upside: +99.20%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $13.94
Upside: -21.09%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $7.40
Upside: +35.14%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $1.21
Upside: +65.29%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.75
Upside: +697.55%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $9.75
Upside: +53.85%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $29.67
Upside: +102.22%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $0.92
Upside: +1,648.63%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $6.05
Upside: +610.74%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $147.06
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $7.35
Upside: +3,981.63%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $0.74
Upside: +1,109.03%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $24.88
Upside: +92.93%